Barclays
KNSA icon

Barclays’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Barclays’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,000
Closed -$675K – 5382
2024
Q3 		$675K Buy
+27,000
New +$658K ﹤0.01% 3591
2024
Q2 		– Sell
-30,000
Closed -$592K – 5102
2024
Q1 		$592K Buy
30,000
+8,000
+36% +$156K ﹤0.01% 3481
2023
Q4 		$386K Buy
+22,000
New +$362K ﹤0.01% 4033

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Barclays's KNSA Position: Q2 2026 in Review

Barclays reduced its Kiniksa Pharmaceuticals (KNSA) stake by 61% in Q2 2026, selling an estimated $1.09M and leaving 13,162 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

Barclays first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. The position peaked at $12M in Q4 2020. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Barclays held 13,162 shares of Kiniksa Pharmaceuticals worth $842K as of Q2 2026.
  • Barclays sold 20,990 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.09M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2890 holding.
  • Barclays first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Barclays's Kiniksa Pharmaceuticals position peaked at $12M in Q4 2020.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.